Poolbeg Pharma (LON:POLB) Trading Down 13.6% – What’s Next?

Poolbeg Pharma PLC (LON:POLB) was down 13.6% on Tuesday . The stock traded as low as GBX 5.96 and last traded at GBX 6.05. 23,044,447 shares changed hands during trading, an increase of 1,199% from the average session volume of 1,774,020 shares. The stock had previously closed at GBX 7.

Analysts Set New Price Targets

Separately, Shore Capital Group restated a “house stock” rating on shares of Poolbeg Pharma in a research note on Monday.

Poolbeg Pharma Trading Down 13.6%

The firm has a market cap of £42.66 million, a P/E ratio of -6.44 and a beta of 1.81. The company’s 50-day moving average is GBX 6.40 and its two-hundred day moving average is GBX 5.09.

Poolbeg Pharma (LON:POLB) last issued its quarterly earnings data on Tuesday, April 28th. The company reported GBX (0.94) EPS for the quarter. Research analysts anticipate that Poolbeg Pharma PLC will post -0.68 EPS for the current fiscal year.

About Poolbeg Pharma

Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company’s lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity.